Case-Based Roundtable™

This roundtable series reviews immunotherapy in patients with unresectable hepatocellular carcinoma as first-line treatment, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series evaluates the use of frontline immunotherapy plus chemotherapy in locally advanced or metastatic biliary tract cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series provides context on the growing number of options for patients with non–small cell lung cancer and KRAS G12C mutations, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series assesses later-line treatment of patientswith relapsed/refractory multiple myeloma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series explores combination treatments for patients with upper gastrointestinal cancer, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series discusses blastic plasmacytoid dendritic cell neoplasms in patients and the ways to identify and provide therapy for this rare disease, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series considers multiple therapies from published clinical trials for patients with relapsed/refractory metastatic clear cell renal cell carcinoma, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series reviews molecular testing in non–small cell lung cancer and potential treatments for patients with EGFR exon 20 mutations, as discussed by key opinion leaders and participants at virtual live events.

This roundtable series provides insights on assessing patients with renal cell carcinoma and how to treat them in the first line based on their risk factors, as discussed by experts in video interviews with Targeted Oncology.

This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.